-
Nanjing Chia Tai Tianqing Lunvatinib was approved to be listed as the third domestic manufacturer
Time of Update: 2021-09-05
On August 16, the NMPA official website showed that Nanjing Chia Tai Tianqing's lenvatinib was approved for listing, becoming the third domestic generic drug of this variety .
The listing of domestic generic drugs may further reduce the price of this variety, which will further benefit the patient population .
-
Top 10 drug sales in the first half of the year announced that 4 drugs fell out of the top 10 sales
Time of Update: 2021-09-05
According to the Henan Province’s previous announcement of the province’s drug online transactions in the first half of 2020, there were 3,500 medical institutions (provincial medical institutions and some retail pharmacies), 2,343 manufacturing companies, and 449 operating companies that traded through the platform in the first half of the year.
-
Venlafaxine Hydrochloride Sustained-Release Capsules, a subsidiary of Renfu Pharmaceutical, obtained FDA approval
Time of Update: 2021-09-05
On August 9, Renfu Medicine issued an announcement stating that its holding subsidiary, Yichang Renfu, had received the US FDA’s approval number for venlafaxine hydrochloride sustained-release capsules, which are suitable for various types of depression, including those accompanied by anxiety.
-
BeiGene's PD-1 new indication is clinically approved
Time of Update: 2021-09-05
On January 12, 2021, BeiGene and Novartis reached a cooperation and licensing agreement to develop, Production and commercialization of the anti-PD-1 antibody Bezean (Tilelizumab), with a total transaction value of up to 2.
-
China Food and Drug Administration: A batch of Philips Jinkewei medical devices is being recalled
Time of Update: 2021-09-05
On August 6, the State Food and Drug Administration issued an announcement to notify Philips Kingway (Shenzhen) Industrial Co.
Details are as follows:Philips Kingway (Shenzhen) Industrial Co.
Philips Kingway (Shenzhen) Industrial Co.
voluntarily recalled its electrocardiograph .
-
Eli Lilly Baritinib receives FDA emergency authorization for single-drug treatment of COVID-19 hospitalized patients
Time of Update: 2021-09-05
Article Source: Immediate Medicine NewsToday, the US FDA revised the emergency use authorization (EUA) of baricitinib (brand name Olumiant), and now authorizes baritinib to be used alone for the treatment of assisted oxygen supply, non-invasive or invasive mechanical ventilation or extracorporeal membrane lung Oxygenation (ECMO) hospitalized adults and pediatric COVID-19 patients 2 years of age or older .
-
Up to 1 billion!
Time of Update: 2021-09-04
Shanghai Jinmante Biological, a wholly-owned subsidiary of CSPC, will obtain the right to develop and commercialize KN026's breast and gastric cancer indications in Mainland China (excluding Hong Kong, Macau and Taiwan), and become the listing of KN026 in Mainland China.
-
The first generic drug outbreak!
Time of Update: 2021-09-04
It was approved for import in May 2017, and its domestic sales scale in 2020 Over 170 million yuan, there are currently 18 domestic companies submitting applications for the listing of the product under the new classification, of which Kelun is the first .
-
Jiangsu raises the per capita financial subsidy standard for resident medical insurance not less than 610 yuan per person per year
Time of Update: 2021-09-04
(Receptionist Wu Rui) Medical Network News on August 24, Jiangsu Provincial Medical Insurance Bureau announced that this year Jiangsu will continue to improve the level of funding for basic medical insurance for urban and rural residents, and consolidate and improve residents' medical insurance benefits .
-
The global epidemic has repeated, and the price of Banlangen has risen again!
Time of Update: 2021-09-04
The production area is smooth, and the price is rising steadily Bozhou Market: Recently, Banlangen's supply has moved well in the market, and inventory has been effectively digested.
-
Boehringer Ingelheim and Anritsu Xirong jointly developed EI-001 and completed clinical application
Time of Update: 2021-09-04
EI-001 antibodies are prepared by a single human B cells obtained technology, which is closely related to target the pathology of vitiligo, hepatitis B and the like .
-
North China Pharmaceutical’s penalty for the suspension of supply is a response from the Fermentation United Procurement Agency
Time of Update: 2021-09-04
Regarding North China Pharmaceutical’s breach of contract, the United Procurement Office has stated in its announcement on August 20 that the company’s ibuprofen sustained-release capsules selected in the third batch of nationally organized drug procurement failed to supply the agreed procurement volume in Shandong Province according to the agreement.
-
North China Pharmaceutical's "National Centralized Procurement Out of Stock" was included in the "List of Violations"
Time of Update: 2021-09-04
(hereinafter referred to as "Huabei Pharmaceutical"), the selected company in the third batch of nationally organized drug centralized procurement of ibuprofen sustained-release capsules, failed to supply the agreed procurement volume in Shandong Province according to the agreement.
-
Bristol-Myers Squibb Opdivo receives FDA approval for adjuvant treatment of urothelial cancer
Time of Update: 2021-09-04
Based on CheckMate- As a result of the safety and effectiveness of 274, Opdivo provides a new FDA-approved therapy that can reduce the risk of disease recurrence or death, and may become a new standard of care for such patients .
-
The Dilemma of Innovation: From the PD(L)1 track to see the innovation choices of Chinese local leading companies
Time of Update: 2021-09-04
Text | Yichun Yiqiu"Double reduction", "School District Housing Reform", "Clinical Value-Oriented Drug Development", "New Coronavirus Mutant". . . Under intensive regulation, the secondary market has
-
Two senior managers of GlaxoSmithKline leave
Time of Update: 2021-09-04
The last working day is September 17, before the arrival of the new head of registration affairs, GSK vice president and GCI regional registration affairs The person in charge, Alexandra Kitashova, is temporarily under the escrow .
-
Hengrui semi-annual report domestic and international research and development pipeline dominates the screen!
Time of Update: 2021-09-04
The product pipeline shown in the content of the semi-annual report With investment in research and development, the market has already made the market feel the determination of Hengrui Pharmaceuticals in the new stage of innovation and internationalization .
-
Why is Pfizer's US$2.26 billion "Don't Eat Me" signal channel favored by many major pharmaceutical companies?
Time of Update: 2021-09-04
26 billion to acquire Trillium and obtain two research therapies that block the CD47-SIRPα signaling pathway .
-
What kind of industry signal does Hengrui adjust its sales team to release?
Time of Update: 2021-09-04
Author: ProbioticsRecently, Hengrui Medicine held an extraordinary general meeting of shareholders. Hengrui Chairman Sun Piaoyang announced the abolition and adjustment plan for the sales team, which
-
Chinese companies independently researched and developed new crown + A and B stream joint detection kits approved for listing
Time of Update: 2021-09-04
The new crown combined influenza A and B virus nucleic acid detection kit independently developed and produced by Chinese biomedical science and technology enterprises has been approved by the National Medical Products Administration.
